Share
Chad Cowan
Century Therapeutics, Inc, a leading biotechnology company focused on developing iPSC-derived cell therapies for immuno-oncology and autoimmune diseases, has announced two key leadership appointments. Morgan Conn, Ph.D., will assume the role of Chief Financial Officer, while Chad Cowan, Ph.D., will take on the position of Chief Scientific Officer. Both leaders will join the Executive Committee. Additionally, Hy Levitsky, M.D., President of Research and Development, will transition from his operational role to serve as an advisor to the company.
Brent Pfeiffenberger, Pharm.D., CEO of Century Therapeutics, welcomed the new appointments, highlighting their importance in advancing Century’s clinical programs and next-generation pipeline. He also acknowledged Dr. Levitsky’s contributions as a foundational figure in Century’s growth and scientific evolution.
